Chlorthalidone for hypertension and edema management

Chlorthalidone is an oral diuretic and antihypertensive medication that helps reduce fluid buildup and lower high blood pressure. It acts over an extended period (48 to 72 hours), making it effective for long-term management of hypertension and edema related to various health conditions.

Chlorthalidone is prescribed for adult patients to manage high blood pressure, either alone or alongside other antihypertensive agents when hypertension is more severe. It is also used as adjunctive therapy to treat edema caused by:

• Congestive heart failure
• Hepatic cirrhosis
• Corticosteroid and estrogen therapy
• Renal dysfunction conditions such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure

In pregnancy, chlorthalidone may be used to treat edema arising from pathological causes but is not appropriate for routine use or for dependent edema due to normal pregnancy changes.

Chlorthalidone

Chlorthalidone works by increasing urine production and promoting the excretion of sodium and chloride through the kidneys. It primarily acts on the cortical diluting segment of the ascending limb of Henle's loop in the nephron, reducing excess fluid in the body. This helps lower blood pressure and decrease swelling caused by fluid retention.

General dosing

Start with the lowest effective dose and adjust based on patient response. A single daily dose taken in the morning with food is recommended. Divided doses are unnecessary.

For hypertension

• Initial dose: 25 mg once daily
• If response is inadequate after a suitable trial, increase to 50 mg once daily
• Further increase up to 100 mg once daily may be considered
• Doses above 100 mg daily typically do not improve effectiveness

For edema

• Initial dose: 50 to 100 mg once daily or 100 mg on alternate days
• Some patients may require up to 150 to 200 mg once daily or on alternate days
• Doses above 200 mg daily generally do not provide greater benefit

Maintenance

Maintenance doses may be lower than initial doses and should be tailored to individual patient response with ongoing monitoring. Effective diuresis and hypertension control can be sustained with continued use.

• Anuria (no urine output)
• Known hypersensitivity to chlorthalidone or other sulfonamide-derived drugs

• Use with caution in severe kidney disease, as chlorthalidone may worsen kidney function or cause azotemia.
• Be careful in patients with liver disease, as fluid and electrolyte balance changes can trigger hepatic coma.
• Patients with sulfonamide allergy or asthma may experience hypersensitivity reactions.
• Monitor for signs of fluid or electrolyte imbalance such as hyponatremia, hypokalemia, and hypochloremic alkalosis.
• Adjust doses cautiously with drugs affecting electrolytes such as digitalis, corticosteroids, or ACTH.
• Alcohol use may increase dizziness risk.
• Not suitable for use in anuria or known hypersensitivity to chlorthalidone or sulfonamide derivatives.

Common or reported adverse reactions include:

• Gastrointestinal: nausea, vomiting, cramping, diarrhea, constipation, gastric irritation, jaundice (intrahepatic cholestatic), pancreatitis
• Central nervous system: dizziness, vertigo, headache, paresthesias, xanthopsia
• Hematologic: leukopenia, agranulocytosis, thrombocytopenia, aplastic anemia
• Skin/hypersensitivity: rash, photosensitivity, purpura, urticaria, necrotizing angiitis, toxic epidermal necrolysis
• Cardiovascular: orthostatic hypotension, which may be worsened by alcohol or sedatives
• Metabolic: hyperglycemia, glycosuria, hyperuricemia, muscle cramps, weakness, restlessness, impotence

Dose reduction or discontinuation may be needed if moderate to severe adverse effects occur.

• May enhance effects of other antihypertensive drugs, including ganglionic peripheral adrenergic blockers.
• Can alter serum electrolytes and interact with medications like digitalis, requiring close monitoring for signs of toxicity.
• Insulin or oral diabetes medication doses may need adjustment due to changes in glucose metabolism.
• Potentiates neuromuscular blockade effects of tubocurarine.
• May decrease vascular response to norepinephrine, though not enough to reduce pressor agent effectiveness.
• May decrease serum protein-bound iodine levels without thyroid dysfunction.

Pregnancy

Chlorthalidone is Pregnancy Category B. Animal studies at high doses have not shown fetal harm, but adequate controlled studies in pregnant women are lacking. Use only if clearly needed. Diuretics do not prevent or treat toxemia of pregnancy. It is indicated for treatment of edema due to pathological causes in pregnancy but not appropriate for physiological or dependent edema from pregnancy itself.

Lactation

Chlorthalidone is excreted in human milk and may cause serious adverse effects in nursing infants. A decision should be made whether to discontinue breastfeeding or the drug, considering the importance of therapy to the mother.

Symptoms of overdose may include nausea, weakness, dizziness, and electrolyte disturbances. No specific antidote exists. Management involves gastric lavage and supportive care. Intravenous fluids with potassium may be given cautiously as needed.

Store between 20°C to 25°C (68°F to 77°F). Protect from light. Dispense in a tight, light-resistant container with child-resistant closure.